Frontlight ResearchEarly access
Not yet taking people in NetherlandsPhase 1/2
Tests a dual-label PSMA tracer to guide prostate cancer surgery
Tests a radioactive and fluorescent PSMA tracer to guide surgery in prostate cancer.
Key facts
- Who runs it
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
- Where
- Amsterdam, NetherlandsSee the site
- Trial code
- Registry title
- DUAL
- Status
- Not yet recruiting
- Phase
- Phase 1/2
- People taking part
- 13 people, planned
- Started
- 1 Aug 2025
- Expected to end
- 1 Aug 2027
- Type of study
- Interventional
- Record updated
- 11 July 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with prostate cancer confirmed by a tissue test, who had a PSMA PET/CT scan showing the tumour and who can have robot-assisted prostate surgery with lymph node removal.
- Age
- 18 years and older
- Sex
- Men only
- Disease stage
- Adenocarcinoma of the prostate confirmed by tissue examination, with a tumour that takes up the PSMA tracer on PET/CT; no minimum or maximum number of lesions.
- Earlier treatment
- A routine PSMA PET/CT within 90 days before surgery. No earlier radiotherapy of the abdomen, no earlier or current chemotherapy or immunotherapy, and no androgen deprivation therapy now or within 6 months before surgery.
- Biomarker or test result
- Tumour that takes up the PSMA tracer on PSMA PET/CT.
Main reasons for not taking part
- Earlier radiotherapy of the abdomen
- Androgen deprivation therapy now or within 6 months before surgery
- Another cancer within 5 years before surgery (skin cancers excepted)
- Earlier or current chemotherapy or immunotherapy
- Reduced kidney function (eGFR below 60ml/min/1,73m2)
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Male, aged 18 years and older
- Histopathologically confirmed adenocarcinoma of the prostate
- Had a routine PSMA PET/CT within 90 days before surgery
- PSMA avid tumor on PSMA PET/CT
- Suitable for RALP +ePLND, as per institutional guidelines (no minimum or maximum lesions on PSMA PET)
- Written and signed informed consent
Who cannot take part
- Previous radiotherapy of the abdomen
- Ongoing androgen deprivation therapy (ADT) or within 6 months prior to surgery
- Previous or ongoing chemotherapy
- Previous or ongoing immunotherapy
- History of other malignancy within 5 years prior to surgery (except skin malignancies)
- History of clinically significant allergies including anaphylaxis
- History of impaired renal function (defined as eGFR<60ml/min/1,73m2)
- Severe claustrophobia interfering with PET/CT or SPECT/CT scanning
Where in Netherlands
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingAmsterdam, NetherlandsNot yet recruiting
About the trial
What the trial wants to find out
To confirm lesion-specific uptake of 99mTc-hPSMA by PCa
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- 99mTechnetium and Cyanine-5 (HybriD) Prostate Specific Membrane Antigen (PSMA) Tracer-gUided Surgery in ProstAte Cancer - a FeasibiLity Study (DUAL study)
- Plain-language title
- Tests a dual-label PSMA tracer to guide prostate cancer surgeryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 11 July 2025